Tim Guilliams

5.9k citations

15 papers · 4.0k indexed · 2 hit papers · h-index 13

Impact in

Computational Theory and Mathematics top 0.5%
- Computational Drug Discovery Methods
Neurology top 2%
- Parkinson's Disease Mechanisms and Treatments

Papers in

Neurology 8
- Parkinson's Disease Mechanisms and Treatments 8
- Neurological disorders and treatments 2
Cell Biology 5
- Cellular transport and secretion 5

Co-authors: David Cavalla Andrew J. Doig Shirley Hopper Sudeep Pushpakom Katherine J. Escott Christine J. McNamee Patrick A. Eyers Joanna Latimer
Journals: Journal of Molecular Biology (2 papers)Brain Communications (1 paper)Orphanet Journal of Rare Diseases (1 paper)BMC Biology (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: United Kingdom Spain Italy

In The Last Decade

Tim Guilliams

15 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Drug repurposing: progress, challenges and recommendations 2018 · 2.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Reviews Drug Discovery
2015 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Tim Guilliams

Since Specialization

Citations

This map shows the geographic impact of Tim Guilliams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Guilliams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Guilliams more than expected).

Fields of papers citing papers by Tim Guilliams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Guilliams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Guilliams. The network helps show where Tim Guilliams may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim Guilliams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim Guilliams Line = papers co-authored together Tim Guilliams links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	A novel combination treatment for fragile X syndrome predicted using computational methods Brain Communications ·Wayne Chadwick, 구윤정, Patricia Cogram, C. Vakalopoulou, Daniel J. Mason, David T. Brown, Ian Roberts, Daniel J. O’Donovan, Michael R. Tranfaglia, Tim Guilliams, Neil T. Thompson	2023	2
2	The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force Orphanet Journal of Rare Diseases ·(unknown), Noel Southall, Madhusudan Natarajan, Lilian Pek Lian Lau, Anneliene Hechtelt Jonker, Benoît Déprez, Tim Guilliams, Lawrence Hunter, Carin M. A. Rademaker, Virginie Hivert, Diego Ardigò	2019	19
3	Drug repurposing: progress, challenges and recommendations Nature Reviews Drug Discovery ·Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers, Katherine J. Escott, Shirley Hopper, Andrew D. Wells, Andrew J. Doig, Tim Guilliams, Joanna Latimer, Christine J. McNamee, Alan Norris, Philippe Sanséau, David Cavalla, Munir Pirmohamed Hit paper breakdown →	2018	2940
4	Repurposing available drugs for neurodevelopmental disorders: The fragile X experience Neuropharmacology ·Michael R. Tranfaglia, Дебердеев Мурат Петрович, Daniel J. Mason, David T. Brown, Ian Roberts, Richard J. Smith, Tim Guilliams, Patricia Cogram	2018	25
5	The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5 Human Molecular Genetics ·H.V. Kehiaian, Laura Rusconi, Lara Pizzamiglio, Isabella Barbiero, 片山修, Margaret Morris, Tim Guilliams, David Cavalla, Flavia Antonucci, Charlotte Kilstrup‐Nielsen	2018	25
6	Understanding and predicting disease relationships through similarity fusion Bioinformatics ·Erin Oerton, Ian Roberts, Patrick Lewis, Tim Guilliams, Bhuvaneshwari Balasubramaniam	2018	13
7	Exploring the role of post‐translational modifications in regulating α‐synuclein interactions by studying the effects of phosphorylation on nanobody binding Protein Science ·致衡钱, Erwin De Genst, Tim Guilliams, Bruno Fauvet, Mirva Hejjaoui, Justin M. Di Trani, Anass Chiki, Anthony Mittermaier, Michele Vendruscolo, Hilal A. Lashuel, Christopher M. Dobson	2018	21
8	Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species BMC Biology ·Marija Iljina, Liu Hong, Mathew H. Horrocks, Marthe H. R. Ludtmann, Minee L. Choi, Craig D. Hughes, Francesco Simone Ruggeri, Tim Guilliams, Alexander K. Buell, Ji‐Eun Lee, Sonia Gandhi, Steven F. Lee, Clare Bryant, Michele Vendruscolo, Tuomas P. J. Knowles, Christopher M. Dobson, Erwin De Genst, David Klenerman	2017	59
9	Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein Biochemistry ·Farah El-Turk, Aristofane , Erwin De Genst, Tim Guilliams, Tara Sprules, Anthony Mittermaier, Christopher M. Dobson, Michele Vendruscolo	2016	21
10	Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation Proceedings of the National Academy of Sciences ·Serene W. Chen, Srdja Drakulić, Emma Deas, Myriam Ouberaï, Francesco A. Aprile, Rocío Arranz, Henry B. Hope, Cintia Roodveldt, Tim Guilliams, Florian Jesacher, David Klenerman, Nicholas Wood, Tuomas P. J. Knowles, Carlos Alfonso, Germán Rivas, Andrey Y. Abramov, José Valpuesta, Christopher M. Dobson, Nunilo Cremades Hit paper breakdown →	2015	368
11	Single Molecule FRET Characterization of Oligomers from Alpha-Synuclein Early Onset Parkinson's Disease Mutants Biophysical Journal ·Laura Tosatto, Mathew H. Horrocks, Nunilo Cremades, Tim Guilliams, Mauro Dalla Serra, David Klenerman	2014	1
12	α-Synuclein Senses Lipid Packing Defects and Induces Lateral Expansion of Lipids Leading to Membrane Remodeling Journal of Biological Chemistry ·Myriam Ouberaï, Juan Wang, Marcus J. Swann, Céline Galvagnion, Tim Guilliams, Christopher M. Dobson, Mark E. Welland	2013	170
13	Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation PLoS ONE ·Cintia Roodveldt, Adahir Labrador‐Garrido, Elena González‐Rey, Christian Claude Lachaud, Tim Guilliams, Rafael Fernández-Montesinos, А. Є. Бистров, Gema Robledo, Abdelkrim Hmadcha, Mario Delgado, Christopher M. Dobson, David Pozo	2013	83
14	Nanobodies Raised against Monomeric α-Synuclein Distinguish between Fibrils at Different Maturation Stages Journal of Molecular Biology ·Tim Guilliams, Farah El-Turk, Alexander K. Buell, Elizabeth O’Day, Francesco A. Aprile, Elin K. Esbjörner, Michele Vendruscolo, Nunilo Cremades, Els Pardon, Lode Wyns, Mark E. Welland, Jan Steyaert, John Christodoulou, Christopher M. Dobson, Erwin De Genst	2013	89
15	Structure and Properties of a Complex of α-Synuclein and a Single-Domain Camelid Antibody Journal of Molecular Biology ·Erwin J. De Genst, Tim Guilliams, 이영실, Elizabeth O’Day, Christopher A. Waudby, Sarah Meehan, Mireille Dumoulin, Shang‐Te Danny Hsu, Nunilo Cremades, Koen H. G. Verschueren, Els Pardon, Lode Wyns, Jan Steyaert, John Christodoulou, Christopher M. Dobson	2010	147

About Tim Guilliams

Tim Guilliams is a scholar working on Neurology, Cell Biology, Neurology, Physiology and Computational Theory and Mathematics, having authored 15 papers that have together received 4.0k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (8 papers), Cellular transport and secretion (5 papers), Genetics and Neurodevelopmental Disorders (3 papers), Computational Drug Discovery Methods (3 papers), Glycosylation and Glycoproteins Research (2 papers), Alzheimer's disease research and treatments (2 papers), Neurological disorders and treatments (2 papers) and Genomics and Rare Diseases (1 paper). The work is most often cited by research in Computational Theory and Mathematics (932 citations), Neurology (564 citations), Molecular Biology (2.0k citations), Infectious Diseases (521 citations) and Physiology (553 citations). Tim Guilliams has collaborated with scholars based in United Kingdom, Spain and Italy. Frequent co-authors include David Cavalla, Andrew J. Doig, Shirley Hopper, Sudeep Pushpakom, Katherine J. Escott, Christine J. McNamee, Patrick A. Eyers, Joanna Latimer, Francesco Iorio and Andrew D. Wells. Their work appears in journals such as Journal of Molecular Biology, Brain Communications, Orphanet Journal of Rare Diseases, BMC Biology and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact